- Home
- CVBF vs DNLI Comparison
CVBF vs DNLI Comparison
Compare CVBF & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CVBF | DNLI |
|---|---|---|
| Founded | 1974 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 2009 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CVBF | DNLI |
|---|---|---|
| Price | $18.88 | $19.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $24.17 | ★ $29.38 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | ★ 5.56 | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.55 | N/A |
| Revenue Next Year | $15.13 | $291.12 |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.01 | $10.57 |
| 52 Week High | $21.48 | $23.77 |
Technical Indicators
Market Signals| Indicator | CVBF | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 45.45 |
| Support Level | $18.16 | $13.28 |
| Resistance Level | $19.56 | $20.12 |
| Average True Range (ATR) | 0.55 | 1.05 |
| MACD | -0.16 | -0.19 |
| Stochastic Oscillator | 16.97 | 22.72 |
Price Performance
Historical ComparisonAbout CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.